Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Lasa Supergenerics Ltd

About the Company - Lasa Supergenerics Ltd

Lasa Supergenerics Ltd. is a Public Limited Listed company incorporated on 11/11/2016 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24233MH2016PLC274202 and registration number is 274202. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company’s Total Operating Revenue is Rs. 137.13 Cr. and Equity Capital is Rs. 40.67 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Chemicals - Speciality - OthersPlot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722investor@lasalabs.com
http://www.lasalabs.com
Management
NamePosition Held
Dr. Omkar Pravin HerlekarChairman & Managing Director
Mr. Shivanand G HegdeWhole Time Director
Mr. Ajay Hareshlal SukhwaniIndependent Director
Ms. Manali Roop BhagtaniIndependent Director
Ms. Ekta Avtar GurnasinghaniIndependent Director
Mr. Hardesh Raja TolaniIndependent Director

Lasa Supergenerics Ltd. Share Price Update

Share PriceValue
Today₹32.82
Previous Day₹34.21

Basic Stock Data of Lasa Supergenerics Ltd

Market Cap 160 Cr.
Current Price 31.8
High / Low41.2/17.1
Stock P/E
Book Value 22.6
Dividend Yield0.00 %
ROCE11.9 %
ROE14.0 %
Face Value 10.0

Data Source: screener.in

Lasa Supergenerics Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales54.6953.9939.1036.0734.1115.7451.2128.8833.6631.7035.3230.5624.30
Expenses41.8941.2430.0131.4432.8616.9240.4637.0133.9934.1630.9826.5123.25
Operating Profit12.8012.759.094.631.25-1.1810.75-8.13-0.33-2.464.344.051.05
OPM %23.40%23.62%23.25%12.84%3.66%-7.50%20.99%-28.15%-0.98%-7.76%12.29%13.25%4.32%
Other Income0.000.020.000.01-11.880.014.240.01-2.470.86-18.970.000.08
Interest0.190.080.030.030.000.010.010.010.840.430.410.370.56
Depreciation4.074.093.943.473.453.593.613.073.093.094.172.652.68
Profit before tax8.548.605.121.14-14.08-4.7711.37-11.20-6.73-5.12-19.211.03-2.11
Tax %17.45%23.84%25.78%29.82%2.41%1.05%-6.68%-7.95%2.08%-17.38%21.92%580.58%99.05%
Net Profit7.056.563.800.81-13.74-4.7112.13-12.08-6.61-6.02-15.00-4.95-0.02
EPS in Rs1.731.610.930.20-3.38-1.162.98-2.97-1.63-1.48-2.99-0.99-0.00

Lasa Supergenerics Ltd Quarterly Chart

Lasa Supergenerics Ltd Profit & Loss

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales0199244170167201137130122
Expenses0153202158137154120136115
Operating Profit0464111304716-67
OPM %23%17%7%18%24%12%-5%6%
Other Income0-243000-8-18-18
Interest01211882042
Depreciation0818191716151313
Profit before tax0215-16530-6-42-25
Tax %-10%19%25%23%23%13%9%
Net Profit0212-12423-5-39-26
EPS in Rs5.40-5.260.895.60-1.31-7.71-5.46
Dividend Payout %0%0%0%0%4%-24%0%

Lasa Supergenerics Ltd Profit & Loss Yearly Chart

Lasa Supergenerics Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:-12%
3 Years:-8%
TTM:-20%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:88%
Stock Price CAGR
10 Years:%
5 Years:8%
3 Years:-23%
1 Year:20%
Return on Equity
10 Years:%
5 Years:0%
3 Years:1%
Last Year:-14%

Lasa Supergenerics Ltd Balance Sheet

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital0023234141505050
Reserves07594821011181086863
Borrowings011610785481920221
Other Liabilities03763694229312452
Total Liabilities0228287258232208209164166
Fixed Assets0119170162152143137119115
CWIP0307700555
Investments000000000
Other Assets080110908065674046
Total Assets0228287258232208209164166

Lasa Supergenerics Ltd Reserves and Borrowings Chart

Lasa Supergenerics Ltd Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 0-3404114419-17
Cash from Investing Activity 00-44-7-2-4-311
Cash from Financing Activity 004-33-10-36-0-4
Net Cash Flow0-30-0216-10

Lasa Supergenerics Ltd Financial Efficiency Indicators

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days6463624527507
Inventory Days939090101564648
Days Payable71102170130416832
Cash Conversion Cycle8751-1816422822
Working Capital Days5844-2313512-17
ROCE %42%13%-4%7%17%1%-12%

Lasa Supergenerics Ltd Financial Efficiency Indicators Chart

Lasa Supergenerics Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters64.47%64.47%64.47%64.47%45.01%43.78%43.78%43.78%43.78%53.65%53.65%53.65%
FIIs0.00%0.00%0.02%0.01%0.06%0.00%0.40%0.00%0.00%0.00%0.00%0.00%
Public35.53%35.53%35.51%35.52%54.93%56.21%55.82%56.21%56.21%46.34%46.34%46.34%
No. of Shareholders19,20719,12122,04823,06624,82727,85930,08729,69228,93628,81828,03127,770

Lasa Supergenerics Ltd Shareholding Pattern Chart

No. of Lasa Supergenerics Ltd Shareholders

This stock is not held by any mutual fund

Lasa Supergenerics Ltd ROCE Trend

Lasa Supergenerics Ltd EPS Trend

Lasa Supergenerics Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)-7.71-1.305.601.26-5.27
Diluted EPS (Rs.)-7.71-1.305.601.26-5.27
Cash EPS (Rs.)-5.032.129.495.163.18
Book Value[Excl.RevalReserv]/Share (Rs.)23.6136.5439.0734.7846.05
Book Value[Incl.RevalReserv]/Share (Rs.)23.6136.5439.0734.7846.05
Dividend / Share (Rs.)0.000.250.250.000.00
Revenue From Operations / Share (Rs.)25.8633.7149.7641.1374.16
PBDIT / Share (Rs.)-0.953.8611.627.426.66
PBIT / Share (Rs.)-3.630.417.733.16-1.78
PBT / Share (Rs.)-8.44-1.537.251.16-7.04
Net Profit / Share (Rs.)-7.71-1.325.600.89-5.26
PBDIT Margin (%)-3.6911.4423.3618.048.97
PBIT Margin (%)-14.051.2315.547.67-2.40
PBT Margin (%)-32.62-4.5214.572.83-9.49
Net Profit Margin (%)-29.80-3.9111.252.16-7.09
Return on Networth / Equity (%)-32.65-3.6114.332.56-11.42
Return on Capital Employeed (%)-15.031.0818.798.22-2.69
Return On Assets (%)-23.57-2.6910.951.56-4.65
Long Term Debt / Equity (X)0.000.000.000.090.43
Total Debt / Equity (X)0.000.000.000.240.65
Asset Turnover Ratio (%)0.710.670.920.680.62
Current Ratio (X)0.911.651.590.990.80
Quick Ratio (X)0.591.391.160.650.50
Inventory Turnover Ratio (X)8.676.134.692.992.27
Interest Coverage Ratio (X)-1.15389.3324.083.721.27
Interest Coverage Ratio (Post Tax) (X)-3.5062.8612.601.450.00
Enterprise Value (Cr.)90.15152.41239.23143.93118.74
EV / Net Operating Revenue (X)0.691.111.180.860.70
EV / EBITDA (X)-18.829.715.064.777.80
MarketCap / Net Operating Revenue (X)0.711.241.200.690.31
Price / BV (X)0.781.141.530.810.50
Price / Net Operating Revenue (X)0.711.241.200.690.31
EarningsYield-0.41-0.030.090.03-0.22

Lasa Supergenerics Ltd Profitability Ratios (%)

Lasa Supergenerics Ltd Liquidity Ratios

Lasa Supergenerics Ltd Liquidity Ratios (%)

Lasa Supergenerics Ltd Interest Coverage Ratios (%)

Lasa Supergenerics Ltd Valuation Ratios

Fair Value of Lasa Supergenerics Ltd Stock

Fair Value: ₹48.41

The stock is undervalued by 52.23% compared to the current price ₹31.8

*Investments are subject to market risks

Strength and Weakness of Lasa Supergenerics Ltd Stock

StrengthWeakness
  1. The stock has a low average Working Capital Days of 20.13, which is a positive sign.
  2. The company has higher reserves (78.78 cr) compared to borrowings (46.44 cr), indicating strong financial stability.
  1. The stock is trading at a high valuation with an average P/B ratio of 5.72 and average Dividend Yield of 1.60%.
  2. The stock has a low average ROCE of 8.00%, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 28.50, which may not be favorable.
  4. The company has not shown consistent growth in sales (152.22) and profit (-4.11).

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lasa Supergenerics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE